Cargando…

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study

OBJECTIVES: To characterize the kinetics of humoral and T-cell responses in rheumatoid arthritis (RA)-patients followed up to 4-6 weeks (T3) after the SARS-CoV-2 vaccine booster dose. METHODS: Health care workers (HCWs, n = 38) and patients with RA (n = 52) completing the messenger RNA vaccination s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farroni, Chiara, Aiello, Alessandra, Picchianti-Diamanti, Andrea, Laganà, Bruno, Petruccioli, Elisa, Agrati, Chiara, Garbuglia, Anna Rosa, Meschi, Silvia, Lapa, Daniele, Cuzzi, Gilda, Petrone, Linda, Vanini, Valentina, Salmi, Andrea, Altera, Anna Maria Gerarda, Repele, Federica, Grassi, Germana, Bettini, Aurora, Vita, Serena, Mariano, Andrea, Damiani, Arianna, Infantino, Maria, Grossi, Valentina, Manfredi, Mariangela, Niccoli, Laura, Puro, Vincenzo, Rosa, Roberta Di, Salemi, Simonetta, Sesti, Giorgio, Scolieri, Palma, Bruzzese, Vincenzo, Benucci, Maurizio, Cantini, Fabrizio, Nicastri, Emanuele, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622025/ https://www.ncbi.nlm.nih.gov/pubmed/36328289 http://dx.doi.org/10.1016/j.ijid.2022.10.035

Ejemplares similares

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
por: Farroni, Chiara, et al.
Publicado: (2022)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2023)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2021)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
por: Alonzi, Tonino, et al.
Publicado: (2022)

Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases
por: Laganà, Bruno, et al.
Publicado: (2019)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2021)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
por: Agrati, Chiara, et al.
Publicado: (2021)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Vitamin D Signaling in Gastro-Rheumatology: From Immuno-Modulation to Potential Clinical Applications
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
por: Petruccioli, Elisa, et al.
Publicado: (2018)

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2020)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
por: Santoro, Annapaola, et al.
Publicado: (2023)

Epidemiology of HEV in the Mediterranean basin: 10-year prevalence in Italy
por: Lanini, Simone, et al.
Publicado: (2015)

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
por: Agrati, Chiara, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
por: Mazzotta, Valentina, et al.
Publicado: (2022)

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination
por: Matusali, Giulia, et al.
Publicado: (2023)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18–40 years old: a possible HIV indicator condition
por: Bibas, Michele, et al.
Publicado: (2021)

Publisher Correction: Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18–40 years old: a possible HIV indicator condition
por: Bibas, Michele, et al.
Publicado: (2021)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
por: Benucci, Maurizio, et al.
Publicado: (2020)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fk4no3q5n8aaoieli2lb3p7fjl